Researchers is demonstrably improved this course of an new therapy for ATTR-CM, leveraging the investigational drug. Preliminary patient information suggests promising outcomes for click here patients affected with the severe illness. This emphasis represents BridgeBio's dedication to managing critical patient demands in the cardiology space. Attr